Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (53,046,000)	$ (33,409,000)
Adjustments to reconcile net loss to cash used in operating activities:
In-process research and development expense	(1,000,000)	5,500,000
Depreciation and amortization expense	62,000	50,000
Stock-based compensation expense	3,591,000	1,820,000
Amortization of premium and accretion of discounts on short-term investments, net	(35,000)	33,000
Changes in operating assets and liabilities:
Prepaid and other current assets	2,891,000	(6,663,000)
Operating lease right-of-use asset and liability, net	(5,000)	20,000
Other assets	(53,000)	366,000
Accounts payable	(2,028,000)	2,862,000
Accrued research and development	4,000	3,834,000
Other accrued liabilities	(286,000)	(2,117,000)
Net cash used in operating activities	(49,905,000)	(27,704,000)
Investing activities
Purchases of short-term investments	(34,764,000)	(136,852,000)
Purchases of property and equipment		(128,000)
Payment of in-process research and development expense		(2,500,000)
Maturities of short-term investments	99,150,000
Net cash provided by (used in) investing activities	64,386,000	(139,480,000)
Financing Activities
Proceeds from initial public offering		121,494,000
Proceeds from the issuance of common stock under the Company's equity incentive plans and employee stock purchase plan	573,000	85,000
Net cash provided by financing activities	573,000	121,579,000
Net increase (decrease) in cash and cash equivalents	15,054,000	(45,605,000)
Cash and cash equivalents at beginning of period	24,780,000	58,863,000
Cash and cash equivalents at end of period	39,834,000	13,258,000
Supplemental schedule of non-cash investing and financing activities:
Conversion of convertible preferred stock to common stock		94,697,000
Non-cash in-process research and development accrual	$ (1,000,000)	$ 3,000,000